Differential reactivity of human mammary artery and saphenous vein to prostaglandin E 2: Implication for cardiovascular grafts

British Journal of Pharmacology

Volumn 163, Issue 4, 2011, Pages 826-834

  Foudi, N ^a,b,c   Kotelevets, L ^a   Gomez, I ^a,b   Louedec, L ^a   Longrois, D ^a   Chastre, E ^a   Norel, X ^a,b  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

EP 3 receptor; EP 4 receptor; human mammary artery; human saphenous vein; prostaglandin E 2; vascular tone

Indexed keywords

11,15 O DIMETHYLPROSTAGLANDIN E2; 17 PHENYLPROSTAGLANDIN E2; 4 [2 [N ISOBUTYL N (2 FURYLSULFONYL)AMINO] 5 TRIFLUOROMETHYLPHENOXYMETHYL]CINNAMIC ACID; GW 627368X; L 826266; MISOPROSTOL; N [(5 BROMO 2 METHOXYPHENYL)SULFONYL] 3 [5 CHLORO 2 (2 NAPHTHYLMETHYL)PHENYL]ACRYLAMIDE; N [2 [4 (4,9 DIETHOXY 1 OXO 1,3 DIHYDRO 2H BENZO[F]ISOINDOL 2 YL)PHENY]ACETYL]BENZENESULFONAMIDE; ONO 8713; ONO AE 1 329; ONO AE 248; PROSTAGLANDIN E RECEPTOR 1; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; SC 51322; SULPROSTONE; UNCLASSIFIED DRUG;

AGED; ARTERY CONSTRICTION; ARTICLE; BLOOD VESSEL GRAFT; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; INTERNAL MAMMARY ARTERY; MALE; PRIORITY JOURNAL; SAPHENOUS VEIN; VEIN DILATATION;

ACRYLAMIDES; AGED; CORONARY ARTERY BYPASS; DINOPROSTONE; FEMALE; HUMANS; ISOINDOLES; MALE; MAMMARY ARTERIES; METHYL ETHERS; MISOPROSTOL; NAPHTHALENES; RECEPTORS, PROSTAGLANDIN E; SAPHENOUS VEIN; SULFONAMIDES; VASCULAR GRAFTING;

EID: 79958068522     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01264.x     Document Type: Article

References (35)

1. Alexander SP, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th edition. Br J Pharmacol 158 (Suppl. 1): S1-254.
2. Almanaseer Y, Rosman HS, Kazmouz G, Giraldo AA, Martin J, (2005). Severe dilatation of saphenous vein grafts: a late complication of coronary surgery in which the diagnosis is suggested by chest x-ray. Cardiology 104: 150-155. (Pubitemid 41291532)
3. Baxter GS, Clayton JK, Coleman RA, Marshall K, Sangha R, Senior J, (1995). Characterization of the prostanoid receptors mediating constriction and relaxation of human isolated uterine artery. Br J Pharmacol 116: 1692-1696.
4. Bayston T, Ramessur S, Reise J, Jones KG, Powell JT, (2003). Prostaglandin E2 receptors in abdominal aortic aneurysm and human aortic smooth muscle cells. J Vasc Surg 38: 354-359. (Pubitemid 41123262)
5. Bishop-Bailey D, Pepper JR, Haddad EB, Newton R, Larkin SW, Mitchell JA, (1997). Induction of cyclooxygenase-2 in human saphenous vein and internal mammary artery. Arterioscler Thromb Vasc Biol 17: 1644-1648. (Pubitemid 27423981)
6. Bishop-Bailey D, Pepper JR, Larkin SW, Mitchell JA, (1998). Differential induction of cyclooxygenase-2 in human arterial and venous smooth muscle: role of endogenous prostanoids. Arterioscler Thromb Vasc Biol 18: 1655-1661. (Pubitemid 28465420)
7. Chaikhouni A, Crawford FA, Kochel PJ, Olanoff LS, Halushka PV, (1986). Human internal mammary artery produces more prostacyclin than saphenous vein. J Thorac Cardiovasc Surg 92: 88-91. (Pubitemid 16096084)
8. Cipollone F, Fazia M, Iezzi A, Zucchelli M, Pini B, De Cesare D, et al,. (2003). Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation 107: 1479-1485. (Pubitemid 36378484)
9. Cocco G, Tarsi G, Bersigotti G, Sgarbi E, (1998). [Acute myocardial infarction following administration of a synthetic analog of prostaglandin E2 in a subject with an intramural course of the anterior intraventricular artery]. G Ital Cardiol 28: 303-307.
10. Cracowski JL, Stanke-Labesque F, Sessa C, Hunt M, Chavanon O, Devillier P, et al,. (1999). Functional comparison of the human isolated femoral artery, internal mammary artery, gastroepiploic artery, and saphenous vein. Can J Physiol Pharmacol 77: 770-776. (Pubitemid 30040948)
11. Cracowski JL, Devillier P, Chavanon O, Sietchiping-Nzepa FA, Stanke-Labesque F, Bessard G, (2001). Isoprostaglandin E2 type-III (8-iso-prostaglandin E2) evoked contractions in the human internal mammary artery. Life Sci 68: 2405-2413. (Pubitemid 32452368)
12. Dashwood MR, (2009). Endothelin-1 and vein graft occlusion in patients undergoing bypass surgery. Eur J Clin Invest 39 (Suppl. 2): 78-87.
13. Davis RJ, Murdoch CE, Ali M, Purbrick S, Ravid R, Baxter GS, et al,. (2004). EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries. Br J Pharmacol 141: 580-585. (Pubitemid 38453250)
14. Foudi N, Kotelevets L, Louedec L, Leseche G, Henin D, Chastre E, et al,. (2008). Vasorelaxation induced by prostaglandin E2 in human pulmonary vein: role of the EP4 receptor subtype. Br J Pharmacol 154: 1631-1639.
15. Goldman S, Zadina K, Moritz T, Ovitt T, Sethi G, Copeland JG, et al,. (2004). Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study. J Am Coll Cardiol 44: 2149-2156. (Pubitemid 39576034)
16. Hung GH, Jones RL, Lam FF, Chan KM, Hidaka H, Suzuki M, et al,. (2006). Investigation of the pronounced synergism between prostaglandin E2 and other constrictor agents on rat femoral artery. Prostaglandins Leukot Essent Fatty Acids 74: 401-415. (Pubitemid 43816853)
17. Jiang H, Weyrich AS, Zimmerman GA, McIntyre TM, (2004). Endothelial cell confluence regulates cyclooxygenase-2 and prostaglandin E2 production that modulate motility. J Biol Chem 279: 55905-55913. (Pubitemid 40066598)
18. Jorapur V, Cano-Gomez A, Conde CA, (2009). Should saphenous vein grafts be the conduits of last resort for coronary artery bypass surgery? Cardiol Rev 17: 235-242.
19. Lauer M, Berentelg J, (2000). [Severe cardiovascular complications relating to Gemeprost therapy]. Zentralbl Gynakol 122: 324-327. (Pubitemid 30399167)
20. Luscher TF, Diederich D, Siebenmann R, Lehmann K, Stulz P, von Segesser L, et al,. (1988). Difference between endothelium-dependent relaxation in arterial and in venous coronary bypass grafts. N Engl J Med 319: 462-467.
21. Mangano DT, (2002). Aspirin and mortality from coronary bypass surgery. N Engl J Med 347: 1309-1317. (Pubitemid 35215321)
22. Norel X, (2007). Prostanoid receptors in the human vascular wall. Sci World J 7: 1359-1374. (Pubitemid 47435435)
23. Norel X, de Montpreville V, Brink C, (2004). Vasoconstriction induced by activation of EP1 and EP3 receptors in human lung: effects of ONO-AE-248, ONO-DI-004, ONO-8711 or ONO-8713. Prostaglandins Other Lipid Mediat 74: 101-112. (Pubitemid 39360223)
24. Proudfoot D, Fitzsimmons C, Torzewski J, Bowyer DE, (1999). Inhibition of human arterial smooth muscle cell growth by human monocyte/macrophages: a co-culture study. Atherosclerosis 145: 157-165. (Pubitemid 29292711)
25. Qian YM, Jones RL, Chan KM, Stock AI, Ho JK, (1994). Potent contractile actions of prostanoid EP3-receptor agonists on human isolated pulmonary artery. Br J Pharmacol 113: 369-374. (Pubitemid 24310729)
26. Schonbeck U, Sukhova GK, Graber P, Coulter S, Libby P, (1999). Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 155: 1281-1291. (Pubitemid 29488935)
27. Shum WW, Le GY, Jones RL, Gurney AM, Sasaki Y, (2003). Involvement of Rho-kinase in contraction of guinea-pig aorta induced by prostanoid EP3 receptor agonists. Br J Pharmacol 139: 1449-1461. (Pubitemid 37174659)
28. Sussmann M, Sarbia M, Meyer-Kirchrath J, Nusing RM, Schror K, Fischer JW, (2004). Induction of hyaluronic acid synthase 2 (HAS2) in human vascular smooth muscle cells by vasodilatory prostaglandins. Circ Res 94: 592-600. (Pubitemid 38387741)
29. Takayama K, Garcia-Cardena G, Sukhova GK, Comander J, Gimbrone MA, Jr, Libby P, (2002). Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem 277: 44147-44154. (Pubitemid 36157844)
30. Turan C, Koc N, Dansuk R, Cengizoglu B, Mericeli DS, Unal O, (2003). Misoprostol administration in first-trimester pregnancies with embryonic demise reduces uterine arterial blood flow. J Matern Fetal Neonatal Med 14: 226-228. (Pubitemid 37340289)
31. Ulmann A, Silvestre L, Chemama L, Rezvani Y, Renault M, Aguillaume CJ, et al,. (1992). Medical termination of early pregnancy with mifepristone (RU 486) followed by a prostaglandin analogue. Study in 16,369 women. Acta Obstet Gynecol Scand 71: 278-283.
32. Walch L, Taisne C, Gascard JP, Nashashibi N, Brink C, Norel X, (1997). Cholinesterase activity in human pulmonary arteries and veins. Br J Pharmacol 121: 986-990. (Pubitemid 27277794)
33. Walch L, de Montpreville V, Brink C, Norel X, (2001). Prostanoid EP(1)- and TP-receptors involved in the contraction of human pulmonary veins. Br J Pharmacol 134: 1671-1678. (Pubitemid 34038100)
34. Wiley KE, Davenport AP, (2002). Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1. Br J Pharmacol 136: 1146-1152. (Pubitemid 34970066)
35. Yang ZH, Buhler FR, Diederich D, Luscher TF, (1989). Different effects of endothelin-1 on cAMP- and cGMP-mediated vascular relaxation in human arteries and veins: comparison with norepinephrine. J Cardiovasc Pharmacol 13 (Suppl. 5): S129-S131. discussion S142. (Pubitemid 19119225)